AMBALALSA vs BPLPHARMA: Stock Comparison

AMBALALSA vs BHARAT PARENTERALSUpdated 20 Aug 26, 4:08 PM ISTNSE & company filings

AMBALALSA shows a higher net margin, while BHARAT PARENTERALS shows a lower P/E and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AMBALALSA leads 4; BPLPHARMA leads 3 of 9

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AMBALALSABPLPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹307 Cr
₹0 Cr
P/E RatioBPLPHARMA has the lower reading
27.1x
0x
P/B RatioAMBALALSA has the lower reading
2.22x
3.18x
EPSBPLPHARMA has the higher reading
₹0.52
₹5.31
Book ValueContext only
₹20.67
₹452.09
Dividend YieldBPLPHARMA has the higher reading
0%
0.13%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

P/E Ratio
BPLPHARMA has a lower P/E
0x vs 27.1x
P/B Ratio
AMBALALSA has a lower P/B
2.22x vs 3.18x
EPS
BPLPHARMA has higher earnings per share
₹5.31 vs ₹0.52
Dividend Yield
BPLPHARMA has a higher dividend yield
0.13% vs 0%
Qtr Sales Growth
AMBALALSA has stronger quarterly sales growth
7,912.25% vs -40.79%
Qtr Profit Growth
AMBALALSA has stronger quarterly profit growth
13,108.64% vs 202.63%
Net Margin
AMBALALSA has a higher net margin
8.8% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricAMBALALSABPLPHARMA
Live Price₹47.74₹1,547
Day Change3.07%2.46%
Volume2.46 L23
52-Week High₹49.98₹1,649
52-Week Low₹30.15₹1,125.7
Distance from 52W High-4.48%-6.19%

Valuation

MetricAMBALALSABPLPHARMA
Market Cap₹307 Cr₹0 Cr
P/E Ratio27.1x0x
P/B Ratio2.22x3.18x
EPS₹0.52₹5.31
Book Value₹20.67₹452.09
Dividend Yield0%0.13%

Growth

MetricAMBALALSABPLPHARMA
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth7,912.25%-40.79%
Qtr Profit Growth13,108.64%202.63%

Profitability & Leverage

MetricAMBALALSABPLPHARMA
ROE18.48%
ROCE14.73%
Net Margin8.8%0%
Operating Margin262.56%
Debt to Equity0.19x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAMBALALSABPLPHARMA
Promoter Holding31.36%67.2% 0.03 pp
FII Holding0%0.11%
DII Holding0.01%1.37% 0.31 pp
Public Holding68.64%31.31% 0.35 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AMBALALSA and BHARAT PARENTERALS.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.